Clinical trials: Patient Comfort and Safety
- Condition Patient Comfort and Safety
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Drug Safety
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
The purpose of this study is to evaluate and compare overall patient comfort profile between an Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients…
- Trial name
- NCT01475097
- Testing
- Iodixanol, Iopamidol
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- GE Healthcare
Patient Comfort and Safety
Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis
The purpose of this study is to evaluate and compare overall patient comfort profile between the Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients…
- Trial name
- NCT01376089
- Testing
- Iodixanol, Iopamidol
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- GE Healthcare
Dyskinesia, Levodopa Induced Dyskinesia (LID)
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed…
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease
- Trial name
- EASE LID (NCT02136914)
- Testing
- ADS-5102
- Where
- 46 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Skin Laxity
Simulines Non-Inferiority Pivotal Study
Up to 260 subjects presenting with skin laxity on the face and neck will be randomized to one of two treatment groups. Subjects meeting all entrance criteria will receive study treatment, then complete two post treatment phone…
- Trial name
- NCT02736825
- Testing
- Ulthera System with standard transducer, Ulthera System with prototype 2 simulines transducer
- Where
- 8 sites in United States
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Ulthera, Inc
Dyskinesia, Levodopa-Induced Dyskinesia (LID)
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed…
- Conditions
- Dyskinesia, Levodopa-Induced Dyskinesia (LID), Parkinson's Disease (PD)
- Trial name
- EASE LID 3 (NCT02274766)
- Testing
- ADS-5102
- Where
- 51 sites in United States, Austria and 3 more
- Volunteers
- 77 people
- Sponsor
- Adamas Pharmaceuticals, Inc.